Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

hedgehog inhibitor NLM-001

A Hedgehog (Hh) pathway inhibitor, with potential immunomodulating and antineoplastic activities. Upon administration, Hh inhibitor NLM-001 targets the Hh pathway and disrupts the tumor microenvironment (TME) by decreasing cancer-associated fibroblasts and promoting immune cell infiltration into the TME. This may increase tumor penetration of chemotherapeutics and may enhance the activity of immunomodulating agents, such as immune checkpoint inhibitors. Hh signaling overactivation may increase tumor cell proliferation and may lead to tumor immunosuppression and drug resistance.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	Hh inhibitor NLM-001
Code name:	NLM 001 NLM-001 NLM001

hedgehog inhibitor NLM-001

Search NCI's Drug Dictionary